A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The intent of this study is to define more precisely the natural history and immunopathogenesis of MAC disease in the HIV-infected population. It is suggested that MAC disease in AIDS patients results both from specific immunologic deficiencies caused by HIV infection of the host and as a result of specific mycobacterial virulence properties. Therefore, aggressive antiretroviral drug treatment of HIV-infected patients at risk for DMAC due to specific immune deficiencies will improve these immune functions in such a manner as to resist DMAC.
A total of 85 patients will be stratified at base...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- You may be eligible for this study if you:
- • Are HIV-positive.
- • Have a CD4 count under 50 cells/mm3 or between 100 and 250 cells/mm3 within 30 days of study entry.
- • Have at least one symptom (e.g., fever, diarrhea, or weight loss) suggestive of MAC infection.
- • Have MAC infection with 7 days or less of MAC treatment.
- • Have an HIV blood level greater than 10,000 copies/ml within 30 days of study entry.
- • Are 18 years of age or older.
- • Exclusion Criteria
- You will not be eligible for this study if you:
- • Have any active infection (except for MAC in Group 2 patients) or any cancer.
- • Are unable to follow an acceptable anti-HIV drug regimen (Groups 2 and 3).
- • Are pregnant or breast-feeding.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Los Angeles, California, United States
Indianapolis, Indiana, United States
New York, New York, United States
Columbus, Ohio, United States
West Columbia, South Carolina, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Seattle, Washington, United States
San Diego, California, United States
Chicago, Illinois, United States
New York, New York, United States
Rochester, New York, United States
Cleveland, Ohio, United States
Stanford, California, United States
Washington, District Of Columbia, United States
Miami, Florida, United States
Buffalo, New York, United States
Cincinnati, Ohio, United States
Philadelphia, Pennsylvania, United States
Galveston, Texas, United States
Dallas, Texas, United States
Atlanta, Georgia, United States
Indianapolis, Indiana, United States
New York, New York, United States
Dallas, Texas, United States
Patients applied
Trial Officials
Rob Roy MacGregor
Study Chair
David Perlman
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials